Development pipeline

Civacir®

Civacir® is a human hepatitis C immunoglobulin (HCIg) that neutralises hepatitis C viruses (HCV). It is being studied in the USA in a phase III clinical trial in patients who required a liver transplant as a result of chronic hepatitis C infection. The objective is prevention of HCV reinfection of the transplanted organ.

Press releases

Biotest establishes basis for significantly higher earn...

10.11.2015, News

Biotest establishes basis for significantly higher earnings potential - Profitable core business despite setback in Q3 2015 - Focus on core business increases planning reliability - Good ... [More]

Letter to Shareholders

06.11.2015, News

LETTER TO SHAREHOLDERS November 4, 2015 Dear Shareholders, The past weeks have been challenging for all of us. As you know, we announced impairments totalling EUR 84 million on 20 October 2015, ... [More]

Impairment of US business and investments in Europe

20.10.2015, News

Biotest: Impairment of US business and investments in Europe Dreieich, 20 October 2015. Biotest AG announces impairments today totalling to EUR 84 million, leading to a negative third-quarter ... [More]

Biotest increases revenues in first half year 2015 by 8...

11.08.2015, News

Biotest increases revenues in first half year 2015 by 8.9% - Clinical development of BT-061 will be discontinued - Capacity expansion at headquarter Dreieich on schedule - Board of ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest increases sales by 11,5% compared to previous y...

12.11.2014, News

Biotest increases sales by 11,5% compared to previous year - Good interim results of R&D projects Civacir(R) and Tregalizumab (BT-061) - Building permission for capacity expansion in ... [More]

Very good results of Civacir(R) (Hepatitis C Immune Glo...

10.11.2014, News

Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial - Preliminary data presented at the Congress of the American Association for the Study of Liver ... [More]

Biotest increases revenues by 8,5%

11.08.2014, News

Biotest increases revenues by 8,5% - EBIT increase by 2,3% - Good Progress in the R&D pipeline - Revised outlook Dreieich, August 11, 2014. The Biotest Group was again able to ... [More]

Outlook revised

11.08.2014, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Outlook revised Dreieich, August 11, 2014. The Management Board revises its outlook. A sales increase of 7% and an operating ... [More]

First patient treated with CivacirTM after Hepatitis C ...

05.08.2013, News

First patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial - 50% of liver transplantations are due to Hepatitis C infection - ... [More]

Biotest consolidates its outstanding position in the he...

23.04.2012, News

Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil - ... [More]

Biotest: Successful launch of plasma protein business i...

07.04.2008, News

Biotest: Successful launch of plasma protein business in the USA · Work to integrate the activities acquired from Nabi Biologics in December 2007 is on schedule · Preparations for a capacity ... [More]

Biotest AG:Biotest AG acquires plasma protein business ...

11.09.2007, News

Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp. · Acquisition of FDA-certified pharmaceutical production facilities and nine plasmapheresis centres · Immediate ... [More]

Biotest AG:Biotest AG acquires plasma protein unit from...

11.09.2007, Adhoc

Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp. Dreieich, 11 September 2007. Biotest AG, Dreieich has acquired the Biologics business unit ('Nabi Biologics') from Nabi ... [More]

Publications

preview

Terrault et al.: Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT)
PDF, 214.92 kB
[ Download ]

Clinical trials

Title

Indication

Status

 
Civacir® (Study 988) Prophylaxis hepatitis C reinfection Study ongoing

A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients

Link clinicaltrials.gov